Abstract | BACKGROUND: A phase I, dose-escalation study of AT-101 with cisplatin and etoposide was conducted to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), safety and pharmacokinetics in patients with advanced solid tumors, with an expanded cohort in patients with extensive-stage small cell lung cancer (ES-SCLC) to assess preliminary activity. METHODS: In the dose escalation portion, increasing doses of AT-101 were administered orally BID on days 1-3 along with cisplatin on day 1 and etoposide on days 1-3 of a 21 day cycle. At the RP2D, an additional 7 patients with untreated ES-SCLC were enrolled. RESULTS: CONCLUSIONS:
|
Authors | William R Schelman, Tabraiz A Mohammed, Anne M Traynor, Jill M Kolesar, Rebecca M Marnocha, Jens Eickhoff, Michael Keppen, Dona B Alberti, George Wilding, Naoko Takebe, Glenn Liu |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 32
Issue 2
Pg. 295-302
(Apr 2014)
ISSN: 1573-0646 [Electronic] United States |
PMID | 23860642
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Etoposide
- Gossypol
- Cisplatin
- gossypol acetic acid
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Cisplatin
(administration & dosage, adverse effects, blood, pharmacokinetics)
- Etoposide
(administration & dosage, adverse effects, blood, pharmacokinetics)
- Female
- Gossypol
(administration & dosage, adverse effects, analogs & derivatives, blood, pharmacokinetics)
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasms
(drug therapy, metabolism)
|